Science - Molecure

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

OncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and

Molecure’s success in development of the mRNA discovery platform

- Molecure confirms that small molecules designed to target mRNA inhibit translation of the encoded protein relevant in cancer - Proof-of-Concept has been demonstrated in a cell assay - Reaching the PoC stage for the first

Luke O’Neill

Luke O’Neill is Professor of Biochemistry in the School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute at Trinity College Dublin, Ireland. He is a world expert on innate immunity and inflammation. His main research interests

Luke O’Neill

Luke O’Neill jest profesorem biochemii w Trinity Biomedical Sciences Institute w Trinity College w Dublinie na Wydziale Biochemii i Immunologii. Jest światowym ekspertem w dziedzinie wrodzonej odporności i stanów zapalnych. Jego główne zainteresowania badawcze obejmują receptory

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Molecure can proceed with clinical trials in the U.S.A – Phase II proof-of-concept study will be the first to treat patients suffering from pulmonary sarcoidosis with OATD-01 In the coming weeks Molecure will also seek the

Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

Closing of equity offering of 2,776,000 series H shares by private placement, offered within the authorised capital, at an issue price of PLN 18 per share Series H shares were subscribed for by 35 investors, new

Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.

The agreement with Simbec-Orion includes organizing and fully executing a proof-of-concept Phase II clinical trial in patients with pulmonary sarcoidosis. The Phase II proof-of-concept study of OATD-01 will be conducted as multi-center and international clinical trial

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study

OATD-01 is a first in class chitotriosidase 1 (CHIT1) inhibitor with disease modifying potential in sarcoidosis and other interstitial lung diseases Clearance of the IND application will pave the way for Molecure to initiate the study

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress

Entering 2023 with strong momentum and a robust pipeline of proprietary, first-in-class compounds First patient dosed in Phase I trial with OATD-02, a novel, first in class dual arginase inhibitor for the treatment of cancer Lead

Search Results for: Science

OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

Molecure’s success in development of the mRNA discovery platform

Luke O’Neill

Luke O’Neill

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Molecure completes successful Secondary Public Offering of approximately USD 12 million with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies

Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.

Molecure Files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study

Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress